GlassScriptPhysician profile
Kari Michelle Ketvertis
NPI 1134191471
$1,768.45
in general payments reported to CMS, 2019-2025
21 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $139 · 2021: $98.16 · 2022: $143 · 2023: $270 · 2024: $340 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $362.29 | 2021-2024 | |
| Novo Nordisk INC | $275.43 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $193.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $173.02 | 2019-2022 | |
| Amgen INC. | $121.35 | 2019-2025 | Evenity |
| Gilead Sciences, INC. | $112.50 | 2023 | Descovy |
| Lilly USA, LLC | $98.76 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $81.51 | 2019-2025 | Arexvy, Bexsero, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $72.49 | 2019 | |
| Astellas Pharma US INC | $45.96 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $28.55 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $26.51 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $25.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.64 | 2022 | |
| Sanofi Pasteur INC. | $23.11 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.08 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.95 | 2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $19.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.17 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.54 | 2019 | |
| Allergan, INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Ketvertis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.